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CASE REPORT
Intracranial Solitary Fibrous Tumor
Eveline Claus*, Patrick Seynaeve†, Jeroen Ceuppens†, Alain Vanneste† and  
Koenraad Verstraete*
Solitary fibrous tumours are rare mesenchymal spindle-cell tumours that occur most often in the visceral 
pleura or liver. If they occur intracranially, they are extra-axially located and develop from the meninges. In 
those cases, the differential diagnosis has to be made with other intracranial extra-axial-located tumours, 
such as meningeoma and hemangiopericytoma. We report a 32-year-old woman with an intracranial soli-
tary fibrous tumour and review the latest literature regarding the imaging characteristics of this tumour.
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Introduction
Solitary fibrous tumours are rare spindle-cell mesenchymal 
tumours, which rarely occur in the central nervous system 
[1, 3]. When they do occur intracranially, they are usually 
extra-axially located [1]. The imaging characteristics of 
these tumours have been scarcely reported and mostly as 
solitary case reports [1]. Pre-operative definitive diagnosis 
is difficult due to the atypical imaging characteristics, but 
the differential diagnosis can be limited by imaging. In this 
case report, we discuss the differential diagnosis of extra-
axial intracranial masses and how to distinguish them 
based on imaging characteristics. Furthermore, a review of 
the literature regarding imaging characteristics of intracra-
nial solitary fibrous tumours was performed. 
Case Report
A 32-year-old patient presented at the emergency depart-
ment with paresthesia in the left arm that migrated to the 
left paravertebral region and the left leg. Her left arm also 
felt heavy. The episode had lasted for less than a minute. 
The patient was a smoker with an unremarkable medical 
history. 
Clinical neurological examination was negative, as were 
the hematological and biochemical results. The electro-
encephalogram (EEG) showed deceleration in the right 
hemisphere, but no other abnormalities. 
The computed tomography (CT) scan showed a large, 
sharply delineated, lobulated mass in the right hemisphere 
(Figure 1). The mass had a broad dural base. There was 
minimal surrounding edema. The tumour showed intense 
heterogeneous contrast enhancement around small, cen-
trally located non-enhancing areas. There was mass effect 
with midline shift, but no subfalcine herniation. 
The magnetic resonance imaging (MRI) scan two days 
later showed a heterogeneous mass which was isoin-
tense on T1-weighted and hyperintense on T2-weighted 
sequences (compared to grey matter Figure 2). After 
administration of gadolinium contrast, there was intense 
heterogeneous enhancement (Figure 3A and B; Figure 4). 
The MRI scan did not show other suspicious lesions. 
Diffusion-weighted imaging (DWI) did not reveal areas 
with diffusion restriction (Figure 2). MRI spectroscopy 
showed a high choline- and myo-inositol peak in both 
short and long echo time series. 
The lesion was resected. Histologic examination showed 
a highly cellular tumour with multiple spindle cells as 
well as focal areas of small cells with elevated cytoplas-
matic index (Figure 5A). Immunohistochemistry showed 
a diffuse, strongly positive CD34 stain (Figure 5B) and 
variably positive Ki-67 as well as strongly positive CD 99 
(Figure 5C) and STAT-6 staining (Figure 5D). The diagno-
sis of an intracranial solitary fibrous tumour was made. 
The tumour was completely resected, without need for 
further treatment. The patient was scheduled for follow-
up MRI after three months.
Differential Diagnosis
Based on the presentation of the tumour, other extra-axial 
intracranial tumours should be considered in the differ-
ential diagnosis. They include meningeoma, hemangio-
pericytoma, dural metastasis, dural lymphoma, isolated 
neurosarcoidosis, and gliosarcoma.
A meningeoma is an extra-axial tumour arising from 
the arachnoïdale cells of the meninges. On CT, a menin-
geoma appears as a sharply delineated hyperdense mass 
with intense homogeneous contrast enhancement. On 
MRI, it is slightly hypo- to isointense compared to grey 
matter on T1-weighted images with homogeneous con-
trast enhancement. The intensity on T2-weighted imag-
ing is variable. In contrast to SFT, a dural tail sign and 
calcification of the tumour can frequently be observed. 
Claus et al: Intracranial Solitary Fibrous TumorArt. 11, pp.  2 of 5 
Figure 2: T2FLAIR and DWI show a midline shift but no diffusion restriction.
Figure 3A and B: Coronal and sagittal T1-weighted images after intravenous administration of gadolinium contrast 
clearly demonstrate the dural tail sign.
Figure 1: Plain CT and contrast-enhanced CT (CECT) show a lobulated, heterogeneously enhancing mass with several 
non-enhancing areas.
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A dural tail sign is not specific to any extra-axial tumour, 
since meningeomas, hemangiopericytomas, and ISFTs 
have all been reported showing a dural tail sign. The 
adjacent bone may help to differentiate meningeoma 
from ISFT. The adjacent bone is often thickened in 
meningeomas; SFT, in contrast, can erode the adjacent 
bone [1, 2]. 
Hemangiopericytoma (HPC) is a mesenchymal tumour 
that is considered identical to SFT when it is located 
extracranially [3, 4]. Intracranially, however, both tumours 
Figure 4: T1-weighted images before and after intravenous administration of gadolinium contrast show heterogeneous 
contrast enhancement with less enhancement of the central areas. 
Figure 5: Hematoxylin-eosin stain with ×200 magnification (A) shows a high concentration of cells. CD 34 stain with 
×200 magnification is positive (B). CD 99 stain (×200) (C), and STAT-6 stain (×200) (D) confirm the positive result.
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exhibit very distinct biological characteristics. HPC is con-
sidered a cellular, more aggressive type of SFT. The more 
benign ‘fibrous’ variant has been termed ‘the fibrous type 
SFT’ [3, 4]. It is hard to distinguish HPC from SFT on imag-
ing. Making the distinction is important, however, since 
HPCs show a high rate of recurrence and late extracranial 
metastasis compared to SFTs. 
Dural metastasis often presents as an enhancing biconvex 
mass displacing the brain. The most common neoplasms 
to develop dural metastasis are breast, lung, and prostate 
cancer. Dural metastasis from melanoma, lymphoma, renal 
cell carcinoma, and gastric carcinoma can also occur but are 
less frequent [5]. Dural metastases are frequently solitary, 
which can lead to misdiagnosis. The skull bone is frequently 
involved. The primary tumour determines the imaging 
characteristics. Most dural metastases are T1-hypointense 
and T2-hyperintense compared to grey matter and show 
diffusion restriction due to high cellularity.
Primary dural lymphoma is a rare dural neoplasm. The 
majority represents low-grade mucosa-associated lymphoid 
tissue (MALT) [5]. The pathogenesis of lymphoid tissue is still 
unclear. A dural lymphoma is typically seen as a hyperdense 
mass on CT, reflecting the high cellularity of the tumour [5]. 
On MRI, it is iso-to hypointense compared to grey matter on 
both T1- and T2-weighted images. It shows diffuse homoge-
neous enhancement after contrast administration. 
Isolated neurosarcoidosis without systemic manifesta-
tion is very rare. It has very indistinct imaging features, 
which makes it difficult to diagnose. Neurosarcoidosis 
presents itself as multiple heterogeneous meningeal 
lesions on MRI. It tends to be isointense on T1-weighted 
images [5]. T1-weighted images after the administration 
of gadolinium contrast show nodular and linear enhance-
ment. On T2-weighted imaging, the hypointense areas 
correlate with fibrocollageneous tissue, while the hyper-
intense areas represent inflammation. Dural lesions are 
rare and are often accompanied with other intracranial 
lesions, typically located in the basal cisterns (e.g. optic 
chiasm, infundible, hypothalamus, cranial nerves).
Gliosarcoma is a rare variant of glioblastoma multi-
forme, with mesenchymal and glial elements. It presents 
as a heterogeneous enhancing mass, with focal areas of 
necrosis and hemorrhage. It is often accompanied by 
marked perilesional oedema. At MRI, it presents itself 
as a heterogeneous T1-hypointense mass with irregular 
rim enhancement, without enhancement of the cen-
tral (necrotic/hemorrhagic) areas. It is surrounded by a 
T2-hyperintense area, representing surrounding edema.
Discussion
Of the aforementioned differential diagnosis, some diag-
noses can be excluded based on the imaging findings. 
Because of the absent alanine peak on the MR spectros-
copy, a meningeoma can be ruled out. Dural metastasis is 
less likely because there is no diffusion restriction and no 
history of primary malignancy. A primary dural lymphoma 
is hypointense on T2-weighted imaging and not hyperin-
tense. Gliosarcoma often shows prominent perilesional 
edema and focal areas of necrosis and hemorrhage, which 
makes the diagnosis less likely. Isolated neurosarcoidosis 
typically presents with multiple lesions and systemic man-
ifestations, which makes this diagnosis unlikely, although 
it cannot be ruled out based on the imaging characteris-
tics alone. An intracranial solitary fibrous tumour and a 
hemangiopericytoma are both compatible with the imag-
ing characteristics. These tumours cannot be distinguished 
from one another through imaging. Histologic examina-
tion is necessary to provide the definitive diagnosis. The 
definitive diagnosis in this case was made by histologic 
examination, which showed a solitary fibrous tumour.
Solitary fibrous tumours are rare spindle-cell mesenchymal 
tumours, which only rarely occur intracranially [1, 3]. They 
have been reported more frequently in the visceral pleura 
and liver, skin, orbits, and paranasal sinuses [1]. When they 
do occur intracranially, they usually develop from mesenchy-
mal cells in the meninges and are extra-axially located [1]. 
The most frequent location is along the tentorium cerebelli, 
followed by the frontal convexity, cerebellopontine angle, 
ventricles, falx cerebri, and posterior fossa [2]. 
Symptoms associated with an ISFT are headache, gait 
disturbance and imbalance, weakness, visual loss, cranial 
nerve dysfunction, nausea/vomiting, and altered mental 
status or confusion [2].
Histological examination shows spindle cells in fascicu-
lar organisation with intercellular collagen bundles [1,6]. 
The tumour is further characterised by a positive CD34 
stain and a positive STAT-6 stain [4, 6]. Some authors also 
reported positive bcl-2 and vimentin staining in ISFTs 
[6, 7]. Dedifferentiated SFT may be positive for p53, while 
the conventional, fibrous component is usually negative 
or shows scarcely scattered positive staining [4]. It is also 
associated with p16 deletion [4]. 
The imaging characteristics of ISFTs have been described 
by Clarençon et al. [1], based on a restrospective cohort 
of nine patients. The majority of these lesions were large, 
multi-lobular and well demarcated. Most were entirely 
solid, while a few showed cystic components. On CT, 
half the masses were heterogeneous. The homogeneous 
lesions were iso- (25%) or hyperdense, with calcifications 
in a minority of the cases [1, 2]. Hypodense lesions have 
also been reported in a few cases [2]. In just more than 
half the cases, there was erosion of the skull adjacent 
to the tumour. There was intense enhancement after IV 
iodinated contrast injection. The reported enhancement 
patterns include homogeneous enhancement as well as 
partial or heterogeneous enhancement [2].
At MRI, a majority of cases are homogeneous on 
T1-weighted imaging (most often isointense). In litera-
ture, the most common presentation is a heterogeneous 
pattern on T2-weighted imaging with hypointense areas 
[1, 7]. This may be explained by the existence of two sepa-
rate components within the tumour. The first component 
is fibrosis, represented by T2-hypointense areas that show 
intense contrast enhancement. The presence of this com-
ponent in a meningeal mass suggests SFT. 
The second hypercellular component presents as a T2 
iso- or hyperintense area with moderate heterogeneous 
enhancement [1, 2]. The combination of these two com-
ponents gives rise to the so-called yin yang sign, which 
is associated with ISFTs. Other reports [2, 7] state that a 
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hypointense or a hyperintense T2 signal is more common 
than a heterogeneous T2 signal, with heterogeneous con-
trast enhancement in most cases. In contrast to menin-
geomas, ISFTs rarely demonstrate contrast enhancement 
of the adjacent meninges (dural tail sign). Significant peri-
tumoral edema is seen in a minority of cases (25%).
In some cases, diffusion-weighted imaging was per-
formed. The cystic components of a multi-cystic SFT 
showed an elevated apparent diffusion coefficient (ADC), 
as expected from the high fluid content (T2 shine through) 
[1]. Solid SFTs showed areas with restricted diffusion on 
ADC maps [1]. There is overlap with the diffusivity of 
meningeomas. Current evidence has only limited informa-
tion about MR spectroscopy in SFTs, with just one patient 
who underwent MR spectroscopy [1]. This showed an 
elevated choline/creatinin ratio and a myoinositol peak. 
Literature states that there are no lactate nor alanine peaks.
Perfusion MRI usually shows an increase of the cerebral 
blood volume (7–7.5 fold rCBV compared to the cerebral 
blood volume of the contralateral white matter) [1]. The 
time to peak and mean transit time is lengthened. 
There is currently no guideline regarding the optimal 
therapeutic approach for SFTs. Total excision of the mass 
is clearly superior to subtotal resection, with a 16-fold 
increase in recurrence ratio with subtotal resection (with-
out adjuvant therapy), compared to total resection. Pre-
operative embolization, pre-operative chemotherapy 
and post-operative adjuvant radiotherapy have been per-
formed. No conclusion can currently be drawn regarding 
the effectiveness of these measures. There is no optimal 
chemotherapeutic regimen for SFTs yet either. 
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